American Society for Radiation Oncology Annual Meeting (ASTRO) | Conference

C. Jillian Tsai, MD, PhD, Discussed Outcomes with SBRT in Lung and Breast Cancer
November 10, 2021

CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about the use of stereotactic body radiation therapy to treat breast and lung cancer.

C. Jillian Tsai, MD, PhD, Discussed the Rationale for Using Consolidation Radiotherapy in Oligoprogressive Metastatic Disease
November 09, 2021

CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about why consolidative radiotherapy may be beneficial against oligoprogression in metastatic breast and lung cancer.

Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer
November 05, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.

Andrew Cook, MD, Discussed Outcomes with Gabapentin vs Opioids to Prevent Treatment-Related Pain in Oropharyngeal Cancer
November 04, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss outcomes with gabapentin compared with opioids for increasing quality of life and decreasing treatment-related pain in oropharyngeal cancer.

Andrew Cook, MD, Discussed the Rational for Using Gabapentin to Prevent CRT-Related Pain in Oropharyngeal Cancer
November 03, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about using prophylactic gabapentin for those receiving chemoradiotherapy for oropharyngeal cancer.

DART Yields Robust Survival Benefit vs Standard of Care in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
October 28, 2021

Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced good quality of life and promising survival benefit after being treated with de-escalated adjuvant radiation therapy.

Stereotactic Body Radiation Therapy Proves Relatively Safe to Use in Oligometastases
October 27, 2021

Patients with up to 5 oligometastases tolerated stereotactic body radiation therapy well, with investigators identifying a relatively safe toxicity profile of grade 2 or higher adverse effects.

Primary Radiotherapy as De-Escalation Strategy Yields Efficacious Survival Outcomes in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
October 27, 2021

Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced efficacious survival benefits from treatment with primary radiotherapy.

Dose-Escalated Radiotherapy Plus STAD Shows Some Benefit for Intermediate-Risk Prostate Cancer
October 27, 2021

Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.

Risk of Cardiotoxicity Not Increased With Radiation Therapy in Certain Patients With HER2-Positive Breast Cancer
October 27, 2021

Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.